Michael J. Fox Foundation to Fund Progressive Predictive Models of Parkinson's Disease
Posted on: Monday, 14 November 2005, 18:00 CST
NEW YORK, Nov. 14 /U.S. Newswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced the launch of a new $2 million initiative to drive the creation of progressive, predictive mammalian models of Parkinson's disease. Such models are crucial research tools for testing neuroprotective and neuroregenerative therapeutic strategies in clinical studies.
While existing models can be useful for studying the pathology of specific mechanisms and pathways implicated in Parkinson's, it is generally recognized that no validated model in standard use currently mimics the disorder's gradual progression in humans.
"A lack of a progressive model has historically made it difficult to identify promising approaches to achieve the 'holy grail' of Parkinson's therapy - delaying, halting or reversing disease progression," said Deborah W. Brooks, president and CEO. "With this initiative, we hope to focus attention and stimulate creative solutions to addressing this long-standing need."
Researchers are invited to submit proposals that seek to create novel models or that propose substantial improvement of existing mammalian models. Ideal models will reproduce as many features of Parkinson's disease as possible, including progressive nigrostriatal dopaminergic degeneration, progressive striatal dopaminergic dysfunction and evidence for relevant protein aggregation. Since the ultimate goal of such a model is to promote the development of neuroprotective therapeutic strategies, the proposed model should have biological relevance to known mechanisms of the disease, and be easy to use and able to be reproduced in a standardized fashion.
Because one laboratory group may not possess the expertise in all steps required to develop and evaluate progressive mammalian models of Parkinson's, collaborations are strongly encouraged. Additionally, in keeping with the Foundation's emphasis on accountability, the program requires the designation of time- dependent milestones. If the project is selected, continued funding throughout the course of the project will be dependent upon successful completion of these milestones.
Letters of intent are due by January 10, 2006. Funding is anticipated by June 2006. For more information, scientists should visit the Foundation's Web site, http://www.michaeljfox.org.
To date, The Michael J. Fox Foundation for Parkinson's Research has funded more than $55 million in research aimed at finding a cure for the disease, either directly or through partnerships.
http://www.usnewswire.com
Source: U.S. Newswire
Related Articles
- Kessler Foundation Research Center Study Provides Insight into One of the Most Challenging Symptoms Following a Traumatic Brain Injury
- Protein may predict disease progression
- Jeffrey Modell Foundation and Talecris Biotherapeutics, Inc. Expand Diagnostic Services for Primary Immunodeficiencies at Children's Hospital Boston
- Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Children's Medical Center
- Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford
- Power3 Identifies Early-Detection Biomarkers for Parkinson's Disease; Can Differentiate Between Parkinson's and Parkinson's-Like Diseases at Early Stages
- Axonyx Completes First Phase I Trial With Posiphen for Alzheimer's Disease Progression
- CORRECTING and REPLACING The Inaugural Albert Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Harold F. Dvorak, M.D.
- Jeffrey Modell Foundation, NHGRI and Affymetrix to Develop Newborn Screening Tests
- Parkinson's Disease Progression Described
 |
 |
User Comments (0)
RSS Feeds